| Gene Set | Leading Edge Genes |
|---|
| WONG MITOCHONDRIA GENE MODULE | NDUFS5, DLD, ATP5I, ATP5C1, VDAC3, MRPL49, MRPL40, NDUFA1, ATP5H, TFAM, NDUFB5, PDK3, NDUFB3, ATP5O, NDUFA6, NDUFA9, ACAT1, SLC25A17, AUH, NDUFS4, ATP5G1, COX4I1, ALDH6A1, ATP5J, NDUFS2, ATP5G3, COX6C, HAX1, SUCLA2, ATP5L |
| WONG EMBRYONIC STEM CELL CORE | SQLE, HDAC1, BUB1, GART, NCBP2, PRPS1, ADSL, TOP2A, ADH5, ATP5O, GARS, UGDH, ATP5J, KPNA6, FDPS, BANF1, ZNF22, LSM2, DLAT, CSE1L, RRM1, SUMO1, RPA3, TRIP13, NDUFA9, CCNB2, HADH, KIF23, CCT5, DHX9, XRCC5, CCNC, SDHD |
| STARK PREFRONTAL CORTEX 22Q11 DELETION DN | MGST3, PSMA2, ATP5H, SEC22B, CYC1, NDUFS1, EIF2S1, ADH5, DDX1, PDGFA, UGP2, ATP5J, ST13, FDPS, COPS3, NUP88, TSPAN31, PGRMC2, UQCRC2, EIF2B4, PPP2R5C, PDCD6, ATP5C1, PPT1, PSMA5, VDAC3, MRPL40, SUMO1, NDUFA9, SRP9, RPL36AL, ACAT2, CCT5, IDH1, SMYD2, OAT, CFDP1, SNRPD2 |
| SPIELMAN LYMPHOBLAST EUROPEAN VS ASIAN DN | CDC16, POLE3, PSMA2, RPN2, PEX11B, TIMM17A, PSMB1, RAD50, MRPL49, RASSF2, PRPS1, SPTLC1, EIF2S1, ATP5O, BECN1, GARS, CDC23, SSR2, CAPN7, YWHAQ, CNIH, ZNF22, BET1, CTDSP2, PDCD6, CCDC6, NFATC3, DLD, ASH2L, PPT1, LMAN1, XPNPEP1, RPA3, VPS41, CUL4B, SNRPB2, PTDSS1, NDUFS4, MKRN1, SUMO3, KIFAP3, CCNC, CAP1, RABIF |
| ACEVEDO LIVER TUMOR VS NORMAL ADJACENT TISSUE UP | CTCF, MAGOH, CETN2, PAPSS1, TSG101, KLHL20, IARS2, SLC33A1, PEA15, MRPL40, NCBP2, NDUFB5, RPA3, SMC3, TIPRL, IGBP1, NDUFB3, PSMB2, MSH6, METAP1, TOM1L1, PDIA6, ACP1, SSR2, ZMPSTE24, ARF3, TBCE, KIFAP3, HAX1, CNIH, KDELR2 |
| REACTOME CELL CYCLE MITOTIC | PSMD5, PSMC5, CDC16, UBE2D1, CETN2, ZWINT, BUB1, PSMA2, ORC2L, RAD21, CENPA, PSMB1, PSME2, RPA3, SMC3, PSMB2, CDC23, KIF23, CDK7, DCTN2, PPP2R1B, CDK2, PPP2R5C, DYNLL1 |
| NCI CITRIC ACID CYCLE TCA CYCLE | CS, SDHD, SUCLA2, SDHC |
| PAL PRMT5 TARGETS UP | NNT, PPP1R7, CETN2, TMPO, CETN3, STMN1, RRM1, SLBP, NCBP2, FKBP4, TOPBP1, TRIP13, IGBP1, PSIP1, CCNB2, TTK, KIF23, SPCS2, UBE2E3, PKD2, COPS3, NUP88, CFDP1, TARDBP, EHMT2, LSM2, ERH |
| OUELLET OVARIAN CANCER INVASIVE VS LMP UP | OAT, PSMB2, COPS5, ATP5C1, NDUFS1, PSMA2, KDELR2, DPM1 |
| NUYTTEN EZH2 TARGETS DN | RDBP, BUB1, ZWINT, TMPO, CETN3, CCNB1, GART, CENPA, RASSF2, TRIAP1, SYPL1, ARCN1, TOP2A, TOPBP1, CNOT1, KIF3A, SP3, EXOSC8, AUH, EIF4EBP2, CYB5B, PBXIP1, SPAST, NUP88, YWHAQ, BANF1, LSM5, NEK9, EXOSC2, TMEM97, CASP6, FANCG, HSBP1, CSE1L, DDHD2, TFAM, RPA3, SMC3, CCNB2, TTK, LBR, KIF23, MKRN1, PPP3CB, BRD8, WIPI2, FADS1, ANP32A, KLHL9, HDAC2 |
| MARKEY RB1 ACUTE LOF DN | BUB1, TMPO, CCNB1, RAD21, STMN1, CENPA, CSE1L, EI24, ADSL, SMC3, TOPBP1, OGT, TRIP13, PSIP1, CCNB2, KIF23, TMEM106C, HDAC2, TARDBP, CDK2 |
| NCI SCF SKP2 MEDIATED DEGRADATION OF P27 P21 | PSMB2, PSMD5, PSMC5, PSMD7, PSMA2, PSMB1, PSMD1, PSME2, PSMA4, SKP1A, PSMB7 |
| CORUM PA700-20S-PA28 COMPLEX | PSMB2, PSMC5, PSMD5, PSMD7, PSMA2, PSMB1, PSME2, PSMD1, PSMA4, PSMB7 |
| NCI REGULATION OF ACTIVATED PAK 2P34 BY PROTEASOME MEDIATED DEGRADATION1 | PSMB2, PSMD5, PSMC5, PSMD7, PSMA2, PSMB1, PSME2, PSMA4, PSMD1, PSMB7 |
| REACTOME CELL CYCLE CHECKPOINTS | PSMB2, PSMD5, PSMC5, CDC16, UBE2D1, CDC23, PSMA2, ORC2L, PSMB1, PSME2, RPA3 |
| BIOCARTA PROTEASOME PATHWAY | PSMB2, PSMA2, RPN2, PSMB1, PSMA4, PSMB7, UBE3A, UBE2A |
| CHIANG LIVER CANCER SUBCLASS UNANNOTATED DN | RFC3, POLE3, DAD1, PSMA2, DPM1, RAN, SYPL1, PRPS1, RPA3, PDIA6, ME2, ARPC1A, UBE2E3, COPS3, XRCC5, SNRPD2, LSM2 |
| MORI LARGE PRE BII LYMPHOCYTE UP | RRM1, CENPA |
| BENPORATH MYC MAX TARGETS | |
| CORUM ANTI-HDAC2 COMPLEX | |
| PUJANA BRCA1 PCC NETWORK | |
| DANG BOUND BY MYC | |
| PUJANA BRCA2 PCC NETWORK | |
| REACTOME CONVERSION FROM APC CDC20 TO APC CDH1 IN LATE ANAPHASE | |
| GINESTIER BREAST CANCER ZNF217 AMPLIFIED UP | |
| HORIUCHI WTAP TARGETS DN | |
| NCI PHOSPHORYLATION OF THE APC C | CDC16, UBE2D1, CDC23, CCNB1 |
| TARTE PLASMA CELL VS PLASMABLAST DN | |
| THEILGAARD NEUTROPHIL AT SKIN WOUND DN | |
| CORUM F1F0-ATP SYNTHASE EC 3.6.3.14 MITOCHONDRIAL | ATP5O, ATP5H, ATP5I, ATP5C1, ATP5G1, ATP5J, ATP5L |
| CHOI ATL CHRONIC VS ACUTE DN | |
| NCI APC C CDC20 MEDIATED DEGRADATION OF MITOTIC PROTEINS | CDC16, UBE2D1, CDC23 |
| LINDGREN BLADDER CANCER WITH LOH IN CHR9Q | |
| CORUM PA28-20S PROTEASOME | |
| CORUM CSA COMPLEX | |
| NCI PREFOLDIN MEDIATED TRANSFER OF SUBSTRATE TO CCT TRIC | |
| CASORELLI ACUTE PROMYELOCYTIC LEUKEMIA DN | |
| RODRIGUES THYROID CARCINOMA POORLY DIFFERENTIATED UP | |
| CORUM CHECKPOINT RAD COMPLEX | |
| REACTOME CHOLESTEROL BIOSYNTHESIS | |
| BOYAULT LIVER CANCER SUBCLASS G23 UP | |
| REACTOME FORMATION OF ATP BY CHEMIOSMOTIC COUPLING | ATP5O, ATP5H, ATP5I, ATP5C1, ATP5G1, ATP5J, ATP5L |
| KEGG MISMATCH REPAIR | |
| CAIRO HEPATOBLASTOMA CLASSES UP | |
| REACTOME HOST INTERACTIONS OF HIV FACTORS | |
| REACTOME INACTIVATION OF APC VIA DIRECT INHIBITION OF THE APCOMPLEX | |
| WATANABE RECTAL CANCER RADIOTHERAPY RESPONSIVE UP | |
| KEGG AMINOACYL TRNA BIOSYNTHESIS | |
| REACTOME APCDC20 MEDIATED DEGRADATION OF CYCLIN B | |
| MEINHOLD OVARIAN CANCER LOW GRADE DN | CCNB2 |
| KAUFFMANN DNA REPAIR GENES | |
| NCI REGULATION OF APC C ACTIVATORS BETWEEN G1 S AND EARLY ANAPHASE | |
| REACTOME DNA REPLICATION PRE INITIATION | |
| REACTOME TRANSFORMATION OF LANOSTEROL TO CHOLESTEROL | |
| REACTOME CITRIC ACID CYCLE | |
| REACTOME PROCESSING OF CAPPED INTRON CONTAINING PRE MRNA | |
| NCI VPU MEDIATED DEGRADATION OF CD4 | |
| NCI TRANSFORMATION OF LANOSTEROL TO CHOLESTEROL | |
| PUJANA XPRSS INT NETWORK | |
| RAMALHO STEMNESS UP | |
| NCI SNRNP ASSEMBLY | |
| DING LUNG CANCER EXPRESSION BY COPY NUMBER | |
| YAO TEMPORAL RESPONSE TO PROGESTERONE CLUSTER 13 | |
| KEGG OXIDATIVE PHOSPHORYLATION | |
| KEGG PARKINSONS DISEASE | |
| KEGG PROTEIN EXPORT | |
| LASTOWSKA NEUROBLASTOMA COPY NUMBER DN | |
| NCI APC C MEDIATED DEGRADATION OF CELL CYCLE PROTEINS | CDC16, UBE2D1, CDC23 |
| GARY CD5 TARGETS DN | |
| NCI APC CDC20 MEDIATED DEGRADATION OF NEK2A | CDC16, UBE2D1, CDC23 |
| MANALO HYPOXIA DN | |
| BYSTRYKH HEMATOPOIESIS STEM CELL AND BRAIN QTL CIS | |
| RICKMAN METASTASIS UP | |
| GRADE COLON AND RECTAL CANCER UP | |
| CORUM 20S PROTEASOME | |
| CORUM 26S PROTEASOME | |
| NCI CONVERSION FROM APC C CDC20 TO APC C CDH1 IN LATE ANAPHASE | CDC16, UBE2D1, CDC23 |
| NOUZOVA TRETINOIN AND H4 ACETYLATION | |
| WEST ADRENOCORTICAL TUMOR UP | |
| CORUM ANAPHASE-PROMOTING COMPLEX | |
| YU MYC TARGETS UP | |
| ZHONG RESPONSE TO AZACITIDINE AND TSA DN | |
| KINSEY TARGETS OF EWSR1 FLII FUSION UP | |
| REACTOME S PHASE | |
| BARRIER COLON CANCER RECURRENCE UP | |
| PUJANA BRCA CENTERED NETWORK | |
| CROMER METASTASIS UP | |
| NCI APC C CDC20 MEDIATED DEGRADATION OF CYCLIN B | CDC16, UBE2D1, CDC23, CCNB1 |
| MOREAUX MULTIPLE MYELOMA BY TACI DN | |
| NCI INACTIVATION OF APC C VIA DIRECT INHIBITION OF THE APC C COMPLEX | CDC16, UBE2D1, CDC23 |
| CORUM SNF2H-COHESIN-NURD COMPLEX | |
| RHODES CANCER META SIGNATURE | |
| NCI VIF MEDIATED DEGRADATION OF APOBEC3G | |
| NCI FORMATION OF ATP BY CHEMIOSMOTIC COUPLING | |
| CORUM RAD17-RFC-9-1-1 CHECKPOINT SUPERCOMPLEX | |
| CORUM CSA-POLIIA COMPLEX | |
| NCI DEGRADATION OF BETA CATENIN BY THE DESTRUCTION COMPLEX | |
| REACTOME PHOSPHORYLATION OF THE APC | CDC16, UBE2D1, CDC23, CCNB1 |
| KEGG NUCLEOTIDE EXCISION REPAIR | |
| REACTOME CYCLIN E ASSOCIATED EVENTS DURING G1 S TRANSITION | |